Finafloxacin MIC values were generally lower than those of ciprofloxacin and moxifloxacin at pH 7.2, and substantially lower at pH 5.8. All three antibiotics appear to be extruded to some extent by the BpeAB-OprB and BpeEF-OprC efflux pumps, but not AmrAB-OprA. The data confirm that BpeEF-OprC is a major fluoroquinolone resistance mechanism in B. pseudomallei, which bestows high-level ciprofloxacin and moxifloxacin resistance. At pH 7.2 the MICs of both fluoroquinolones are 2 mg/L for 1026b versus 32 mg/L (ciprofloxacin) and 16 mg/L (moxifloxacin) for the BpeEF-OprC-expressing strain Bp282. While the finafloxacin MIC value is higher for the BpeEF-OprC-expressing strain when compared with the 1026b prototype control (2 versus 0.25 mg/L at pH 7.2 and 2 versus 0.125 mg/L at pH 5.8, respectively), the susceptibility of B. pseudomallei to finafloxacin is less affected by efflux than ciprofloxacin and moxifloxacin, especially at acidic pH.
11 Mima T, Schweizer HP. The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broadspectrum drug efflux system. Antimicrob Agents Chemother 2010; 54: 3113-20. 1 and published in this journal. This paper highlighted that a significant proportion of carbapenem-resistant Enterobacteriaceae carriers remained colonized for up to 1 year in the healthcare setting, with some potential consequences in terms of cross-transmissions and infections. Carbapenemase-producing Enterobacteriaceae (CPE) represent a major and growing public health threat. 2, 3 Very few options remain for the treatment of CPE infections, and infection control measures play a major role in reducing transmission. Selective digestive decontamination of patients with CPE carriage raised the risk of decolonization-associated drug resistance and poor effectiveness.
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1,4,5 Therefore, non-antibiotic strategies are of particular interest to avoid any risk of cumulative antibiotic resistance. Faecal microbiota transplantation (FMT) appears to be a promising approach to restore a normal intestinal microbiota and has been widely used successfully in recurrent Clostridium difficile infections 6, 7 and to eradicate colonization with CPE 8 or ESBL-producing Enterobacteriaceae. 9 The aim of this exploratory study was to evaluate the effectiveness of FMT against CPE colonization in a murine model of CPE digestive carriage.
Ethics approval (reference 2015041415088410/APAFIS513) was obtained from the Ethics Committee for Animal Experimentation of Pays-de-la-Loire, France. Experiments were conducted according to the European directives concerning the use of animals in research (86/609/EEC). A murine model of CPE colonization was first implemented. Eight-week-old female Swiss mice were exposed to a combination of antibiotics to disrupt their gut microbiome. Oral administration of ceftriaxone (25 mg/kg), metronidazole (25 mg/kg) and vancomycin (50 mg/kg) was performed once daily from day 1 to day 5. A New Delhi metallo-b-lactamase (NDM-1)-producing Escherichia coli (5 % 10 9 cfu/mL) was orally administered on each of days 4, 5 and 8 during and after the end of antibiotic exposure. Mice were then randomly assigned on day 9 to receive 200 lL of saline solution or FMT once daily for 3 days. FMT was performed using a saline solution of pooled stools at 50 mg/mL collected from the same mice before treatment. Stool cultures were performed on selective medium for CPE detection (Chrom ID CARBA, bioMérieux, France). Commensal flora was also studied on chromogenic medium for Enterobacteriaceae (UTI, Oxoid, UK) and blood agar with colistin and nalidixic acid under aerobic and anaerobic conditions (CNA agar medium, bioMérieux). Bacterial identifications were performed using MALDI-TOF MS (Vitek MS, bioMérieux). Faecal concentrations of CPE in the two groups were compared after treatment by using a Wilcoxon-Mann-Whitney test.
A total of 30 mice (15 in each group) were followed for 2 weeks after FMT or placebo administration. Each mouse was individually housed to prevent cross-contamination. The mean CPE stool concentration before treatment was similar in the two groups (2 % 10 8 and 2.3 % 10 8 cfu/mL for the FMT group and the placebo group, respectively; P " 0.86). Before antibiotic exposure, mouse digestive flora contained 2.2 % 10 7 lactobacilli, 2.2 % 10 7 anaerobes (mainly Bacteroides spp. and Clostridium spp.), 10 7 Enterobacteriaceae and 6.8 % 10 5 enterococci. Antibiotic exposure was associated with a complete disappearance of Enterobacteriaceae and anaerobes, and with a significant reduction in Enterococcus and Lactobacillus populations (mean reduction of 99% and 91% from baseline, respectively). Mice recovered most of these bacteria (except Enterobacteriaceae) on day 8, before the beginning of treatment (FMT versus placebo). Six days after treatment (day 15), the mean CPE concentration was significantly lower among FMT-treated mice compared with the placebo group (8.6 % 10 5 and 1.4 % 10 7 cfu/mL, respectively; P " 0.021) (Figure 1 ). This difference persisted on day 22 (7.2 % 10 5 and 6.5 % 10 6 cfu/mL; P " 0.044). No adverse event was recorded during the protocol.
In our murine model of CPE colonization compared with placebo, FMT was associated with a slight reduction in CPE carriage, reaching statistical significance but remaining insufficient from a clinical point of view. These results are not similar to a previous evaluation of FMT in a murine model of vancomycin-resistant Enterococcus faecium colonization. 10 Indeed, in that model transplanted mice demonstrated an eradication of vancomycin-resistant E. faecium 15 days after FMT. Interestingly, the mice recovered a normal digestive flora with a low level of Enterobacteriaceae within a few days following the last administration of antibiotics. Therefore, the FMT was probably more effective in reinforcing the bacterial diversity than in providing high bacterial loads in the digestive tract. The absence of data from previous control studies on CPE carriage and the low number of mice included in our experiment limit the interpretation of our results. To our knowledge, our model is the first experimental controlled study of the effectiveness of FMT against CPE carriage. Therefore, a strict comparison with other bacterial colonization models cannot be done.
FMT appears to be a potential candidate to accelerate transiently the decrease in CPE load in the digestive tract without any risk of increasing antibiotic resistance. However, because of the slight effect observed in our study, additional experiments are needed to confirm these preliminary data.
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None to declare. Sir, In recent years, the incidence of MDR bacteria has dramatically increased worldwide. 1 Ceftolozane/tazobactam is a novel antibiotic agent that combines a newly created cephalosporin with an established b-lactam b-lactamase inhibitor. This drug is active against Pseudomonas aeruginosa, including MDR strains, and other Gram-negative bacteria, including most ESBL-producing Enterobacteriaceae. 2 Ceftolozane/tazobactam has proven effective for the treatment of complicated intra-abdominal and urinary tract infections, 3, 4 and is currently being studied in a multicentre randomized clinical trial for use in ventilator-associated pneumonia. 5 However, to our knowledge, very limited data are available with regard to the use of ceftolozane/tazobactam for the treatment of other infection sites. Here we report the case of a patient with a complicated skin and soft-tissue infection, due to an MDR strain of P. aeruginosa, successfully treated with ceftolozane/tazobactam.
A man in his mid-fifties was admitted to the emergency room due to pain and erythema in his right lower extremity. He had a past medical history of obesity and diabetes mellitus with severe microvascular and macrovascular disease. He had received multiple vascular surgery interventions due to grade IV chronic ischaemic disease in both lower extremities. At admission, CT of the limb showed an abscess surrounding the left femoropopliteal bypass. Blood cultures were positive for Streptococcus pyogenes, and abscess samples taken percutaneously revealed S. pyogenes and MRSA. Conservative medical treatment with penicillin and linezolid was initiated, but signs of infection worsened over the next several days, eventually requiring transfemoral amputation of the extremity on the 21st day of hospitalization. Several days later, fever reappeared and amputation stump infection was suspected. Surgical site cultures grew P. aeruginosa (Table 1) and ESBL-producing Klebsiella pneumoniae. Treatment with imipenem and amikacin was initiated. After 7 days of treatment, fever and clinical signs of infection persisted. Further CT of the limb showed a small abscess at the surgical site. Abscess samples were obtained for culture, which revealed MDR P. aeruginosa (only susceptible to colistin and tobramycin). Treatment with colistin (9 million IU divided into two doses, given every 12 h) and tobramycin (5 mg/kg, administered once daily) was started. Fever and elevation of acute-phase reactants (38 C temperature, 14 220 white blood cells/lL, C-reactive protein level 603 mg/L) persisted and the clinical situation was complicated with renal impairment (estimated glomerular filtration rate, 25 mL/min) and neurotoxicity (low consciousness level and disorientation).
